BCL2A1 and ovarian serous adenocarcinoma: The survival analysis showed that patients with serous ovarian cancer with increased BCL2A1 copy numbers had a lower survival probability with a hazard ratio of 1.672 and a log-rank test p-value of 0.10 (Supplementary Figure S7).